{"id":"adjuvant-chemotherapy-ovarian-function-suppression","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Amenorrhea"},{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Adjuvant chemotherapy delivers cytotoxic agents systemically to eliminate residual cancer cells after surgery. Ovarian function suppression (typically via GnRH agonists or oophorectomy) reduces circulating estrogen levels, which may improve outcomes in hormone receptor-positive breast cancer and simultaneously preserves ovarian function and fertility in younger patients by inducing temporary or permanent amenorrhea that protects oocytes from chemotherapy damage.","oneSentence":"This combination treatment uses chemotherapy drugs to kill cancer cells while simultaneously suppressing ovarian function to reduce estrogen production and protect fertility in premenopausal women with breast cancer.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:16.122Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Premenopausal women with early-stage breast cancer (adjuvant setting)"},{"name":"Hormone receptor-positive breast cancer with ovarian function preservation"}]},"trialDetails":[{"nctId":"NCT05879926","phase":"PHASE3","title":"Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-08-31","conditions":"Breast Cancer","enrollment":3960},{"nctId":"NCT00066703","phase":"PHASE3","title":"Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2003-11-03","conditions":"Breast Cancer","enrollment":2672},{"nctId":"NCT04733118","phase":"PHASE2","title":"Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedSIR","startDate":"2021-08-05","conditions":"Early Breast Cancer","enrollment":393},{"nctId":"NCT07213206","phase":"PHASE3","title":"CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-10-07","conditions":"Breast Cancer","enrollment":1500},{"nctId":"NCT00066807","phase":"PHASE3","title":"Premenopausal Endocrine Responsive Chemotherapy Trial","status":"TERMINATED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2003-08","conditions":"Breast Cancer","enrollment":29},{"nctId":"NCT02132390","phase":"PHASE3","title":"Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2014-05","conditions":"Breast Cancer, Chemotherapy Induced Amenorrhea, Ovarian Function Suppression","enrollment":300},{"nctId":"NCT00912548","phase":"PHASE3","title":"Evaluating the Role of the Addition of Ovarian Function Suppression (OFS) to Tamoxifen in Young Women","status":"UNKNOWN","sponsor":"Korean Breast Cancer Study Group","startDate":"2009-05","conditions":"Breast Cancer","enrollment":1234}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":159,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Adjuvant Chemotherapy + Ovarian Function Suppression","genericName":"Adjuvant Chemotherapy + Ovarian Function Suppression","companyName":"NRG Oncology","companyId":"nrg-oncology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Adjuvant chemotherapy combined with ovarian function suppression is a treatment approach studied in clinical trials for early breast cancer. The mechanism of action of adjuvant chemotherapy is not specified in available databases, but ovarian function suppression is often used in conjunction with aromatase inhibitors to reduce estrogen levels in the body.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}